Catalog No.S1662 Synonyms: PN 200-110
Molecular Weight(MW): 371.39
Isradipine is a potent and selective L-type voltage-gated calcium channel blocker, used to treat high blood pressure.
Purity & Quality Control
Choose Selective Calcium Channel Inhibitors
|Description||Isradipine is a potent and selective L-type voltage-gated calcium channel blocker, used to treat high blood pressure.|
Isradipine produces inhibition of both growth cultures and oxygen consumption on epimastigotes of Trypanosoma cruzi Tulahuen strain, at micromolar concentrations. Isradipine is found to be the most potent derivative in both, in growth cultures (I50 = 20.8 mM) and in vivo oxygen uptake (I50 = 31.1 mM). 
|In vivo||Isradipine reduces hypoxia-induced activation of calcium dependent xanthine oxidases, monoamine oxidases, cytosolic phospholipase A(2) and cyclooxygenases (COX-2) along with concomitant decrease in free radical generation and cytochrome c release. Isradipine prevents hypobaric hypoxia along with augmented neurodegeneration and memory impairment induced increased expression of calpain and caspase 3.  Isradipine (at the dose of 1 mg/kg three times a day) reduces ethanol intake by over 70% in ethanol-preferring rats, the reduction in ethanol intake is compensated by a proportional increase in water consumption and the inhibitory effect persisted throughout the 5 days of treatment.  Isradipine significantly reduces the arterial wall collagen contents in both strains, with marked increases in the elastin content in the carotid but not in the aortic wall in spontaneously hypertensive rats.  Isradipine suppresses the reinforcing properties of morphine and cocaine and may be an effective pharmacotherapy for treatment of cocaine and heroin abuse in mice. |
- Nez-Vergara LJ, et al. Gen Pharmacol, 1998, 30(1), 85-87.
-  Barhwal K, et al. Neurobiol Dis, 2009, 34(2), 230-244.
-  Fadda F, et al. Alcohol Clin Exp Res, 1992, 16(3), 449-452.
|In vitro||DMSO||74 mg/mL (199.25 mM)|
|Ethanol||74 mg/mL warmed (199.25 mM)|
|In vivo||Add solvents individually and in order:
2% DMSO+corn oil
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02168842||Active, not recruiting||Parkinson Disease||University of Rochester|National Institute of Neurological Disorders and Stroke (NINDS)|Michael J. Fox Foundation for Parkinsons Research|The Parkinson Study Group||September 2014||Phase 3|
|NCT01895270||Completed||Opioid Dependence||University of Arkansas|National Institute on Drug Abuse (NIDA)||October 2013||Phase 1|Phase 2|
|NCT01784666||Unknown status||Bipolar Disorder||Massachusetts General Hospital||February 2013||Phase 2|
|NCT01658150||Recruiting||Schizophrenia|Schizoaffective Disorder||Icahn School of Medicine at Mount Sinai|Brain & Behavior Research Foundation||September 2012||--|
|NCT01007994||Completed||Hypertension Secondary to Kidney Transplant||Northwell Health|Childrens Hospital of Philadelphia||November 2009||Phase 2|Phase 3|
|NCT00909545||Completed||Parkinson Disease||Northwestern University|Michael J. Fox Foundation for Parkinsons Research|Northwestern University Dixon Fund|The Parkinson Study Group||July 2009||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.